An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesAntibody binding in proximity to the receptor/glycoprotein complex leads to a basal level of virus neutralization.Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelopeA strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoproteinEffect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5Variable region 4 of SIV envelope correlates with rapid disease progression in morphine-exposed macaques infected with SIV/SHIV.PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeysMutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120.Quantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessment of neutralizing activity of anti-HLA antibodies.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Estimating the stoichiometry of human immunodeficiency virus entryThe human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regionsTransitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domainAntibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotypeInfectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells.The V4 and V5 Variable Loops of HIV-1 Envelope Glycoprotein Are Tolerant to Insertion of Green Fluorescent Protein and Are Useful Targets for Labeling.Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.Comparison of Uncleaved and Mature Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimers.
P2860
Q27489000-B5C280EC-D3B8-4143-907F-3B521A21BD8EQ30444158-6C455FF7-D982-4BD4-A1EF-408C28510FFBQ33269794-0007D3EC-76D9-4423-992F-59120DA2005AQ33522232-7E62090B-8565-4D7A-81B1-09B11A263884Q34434753-330D71ED-DAD1-4597-A29D-84BEA654E03EQ35282021-96557566-C7C9-4ED5-BA1A-CEB7FBE67D4EQ35868102-16304B03-C99C-44DD-9896-81F2A5F81F5BQ36098903-FC42D5A4-870C-49B7-A92F-1E4007CFBD34Q36155555-C8BDD9A5-D44A-4D48-9092-BEABD46CF0A9Q36315745-101E502B-5B77-4177-86CE-806C7B77C621Q36404752-C4123B2E-5921-4864-ADB3-8D0B0A443CB6Q36424011-FCAF1022-1436-4743-B288-DC1BD1BBDCA0Q36600380-AB81DBC6-73AB-45E4-A8D9-A773ECCB85CEQ37051613-868E40CF-CD79-4DAA-8181-A8A512FC4E1FQ37099851-6AF73968-EA57-4E3D-ACED-8B4AC75627BDQ37333789-8303EF1B-3FB8-43B9-BA29-00B05365AD71Q39305772-C910533A-C510-4F10-BB8C-0A27564A32B3Q39451862-590D0138-6C6D-464E-98AB-A90342C0C6CAQ39704592-A30B9257-ABA8-4CFD-8179-2A9E8952D16AQ39843176-C0F4B08A-8F05-43E8-8CCB-8254A1C5EBEBQ40096483-25419768-697C-45C6-B6FB-1424B2DADFD3Q40293043-2506339C-4BEB-4DBF-BA30-F07A16D201B0Q41287677-2D4CF30B-6547-430C-9171-D3FF78CEBF11Q41573062-AB2218AF-D456-4624-88A1-BFB859EC8D67Q52721542-7D9DEE32-17AA-47CB-BE01-8F7B3D807C9F
P2860
An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
An unrelated monoclonal antibo ...... viral envelope glycoproteins.
@en
An unrelated monoclonal antibo ...... viral envelope glycoproteins.
@nl
type
label
An unrelated monoclonal antibo ...... viral envelope glycoproteins.
@en
An unrelated monoclonal antibo ...... viral envelope glycoproteins.
@nl
prefLabel
An unrelated monoclonal antibo ...... viral envelope glycoproteins.
@en
An unrelated monoclonal antibo ...... viral envelope glycoproteins.
@nl
P2860
P1433
P1476
An unrelated monoclonal antibo ...... viral envelope glycoproteins.
@en
P2093
Xinping Ren
Xinzhen Yang
P2860
P304
P356
10.1128/JVI.79.9.5616-5624.2005
P407
P577
2005-05-01T00:00:00Z